News | May 12, 2025
Aarti Drugs Ltd Q4 FY2025 consolidated PAT climbs to Rs. 62.86 Cr
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025
The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs.5.71 crores for the Financial Year ended March 31, 2025
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
Subscribe To Our Newsletter & Stay Updated
